Rockwell Medical
Market Cap
US$152.5m
Last Updated
2019/10/17 23:44 UTC
Data Sources
Company Financials +
Executive Summary
Rockwell Medical, Inc. operates as a specialty pharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis.
Snowflake
Fundamentals
Excellent balance sheet with high growth potential.
Similar Companies
Share Price & News
How has Rockwell Medical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
-2.4%
RMTI
1.7%
US Medical Equipment
2.3%
US Market
1 Year Return
-44.3%
RMTI
10.1%
US Medical Equipment
5.6%
US Market
Return vs Industry: RMTI underperformed the US Medical Equipment industry which returned 10.1% over the past year.
Return vs Market: RMTI underperformed the US Market which returned 5.6% over the past year.
Shareholder returns
| RMTI | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.4% | 1.7% | 2.3% |
| 30 Day | -27.6% | -1.7% | -1.0% |
| 90 Day | -20.9% | -1.7% | -0.7% |
| 1 Year | -44.3%-44.3% | 11.0%10.1% | 7.9%5.6% |
| 3 Year | -60.4%-60.4% | 70.4%65.2% | 45.6%36.3% |
| 5 Year | -76.2%-76.2% | 128.5%103.2% | 65.8%47.6% |
Price Volatility Vs. Market
How volatile is Rockwell Medical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
What Kind Of Share Price Volatility Should You Expect For Rockwell Medical, Inc. (NASDAQ:RMTI)?1 month ago | Simply Wall St
Analysts Expect Breakeven For Rockwell Medical, Inc. (NASDAQ:RMTI)1 month ago | Simply Wall St
Is Rockwell Medical (NASDAQ:RMTI) Using Too Much Debt?Valuation
Is Rockwell Medical undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Undervalued: RMTI ($2.39) is trading below our estimate of fair value ($17.01)
Significantly Undervalued: RMTI is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: RMTI is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: RMTI is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
Low PEG Ratio: Insufficient data to calculate RMTI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RMTI is overvalued based on its PB Ratio (5.1x) compared to the US Medical Equipment industry average (3.7x).
Next Steps
Future Growth
How is Rockwell Medical forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
66.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RMTI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).
Earnings vs Market: RMTI is forecast to become profitable over the next 3 year, which is considered above average market growth.
High Growth Earnings: RMTI's loss is forecast to worsen by 0% next year.
Revenue vs Market: RMTI's revenue (33% per year) is forecast to grow faster than the US market (7.3% per year).
High Growth Revenue: RMTI's revenue (33% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: Insufficient data to determine if RMTI's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Rockwell Medical performed over the past 5 years?
-11.6%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: RMTI is unprofitable, and losses have increased over the past 5 years at a rate of -11.6% per year.
Accelerating Growth: Unable to compare RMTI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RMTI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).
Return on Equity
High ROE: RMTI has a negative Return on Equity (-112.59%), as it is currently unprofitable.
Return on Assets
ROA vs Industry: RMTI is currently unprofitable, so its Return on Assets is negative.
Return on Capital Employed
ROCE Improving: RMTI is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is Rockwell Medical's financial position?
Financial Position Analysis
Short Term Liabilities: RMTI's short term assets ($48.3M) exceeds its short term liabilities ($14.8M)
Long Term Liabilities: RMTI's short term assets (48.3M) exceeds its long term liabilities (12.6M)
Debt to Equity History and Analysis
Debt Level: RMTI's debt to equity ratio (6.4%) is considered satisfactory
Reducing Debt: RMTI had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Inventory Level: RMTI has a low level of unsold assets or inventory.
Debt Coverage by Assets: RMTI's debt is covered by short term assets (assets are 25.287380x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RMTI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if RMTI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Rockwell Medical's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate RMTI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate RMTI's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if RMTI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RMTI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RMTI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Rockwell Medical's salary, the management and board of directors tenure and is there insider trading?
1.0yrs
Average management tenure
CEO
Stuart Paul (59yo)
1.1yrs
Tenure
US$7,483,803
Compensation
Mr. Stuart Paul is Chief Executive Officer and Director at Rockwell Medical, Inc. since September 04, 2018 and also serves as it's President. He served as the President of Asia & Pacific (APAC) at Gambro RÂ ...
CEO Compensation Analysis
Compensation vs. Market: Stuart has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the US market.
Compensation vs Earnings: Insufficient data to compare Stuart's compensation with company performance.
Management Age and Tenure
1.0yrs
Average Tenure
55.5yo
Average Age
Experienced Management: RMTI's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Age and Tenure
5.0yrs
Average Tenure
59.5yo
Average Age
Experienced Board: RMTI's board of directors are considered experienced (5 years average tenure).
Insider Trading
Insider Buying: RMTI insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Shares | 1,904 |
| Max Price | US$2.66 |
| Entity | Company |
| Shares | 319 |
| Max Price | US$3.06 |
| Entity | Individual |
| Shares | 2,579 |
| Max Price | US$3.13 |
| Entity | Company |
| Shares | 161,457 |
| Max Price | US$2.99 |
| Entity | Company |
| Shares | 3,658 |
| Max Price | US$3.05 |
| Entity | Individual |
| Shares | 5,519 |
| Max Price | US$3.05 |
| Entity | Individual |
| Shares | 603 |
| Max Price | US$3.05 |
| Entity | Individual |
| Role | Chief Executive Officer President |
| Shares | 10,000 |
| Max Price | US$2.97 |
| Entity | Individual |
| Role | Chief Financial Officer Chief Financial Officer |
| Shares | 10,000 |
| Max Price | US$3.06 |
| Entity | Company |
| Shares | 50,775 |
| Max Price | US$5.58 |
| Entity | Company |
| Shares | 17,863 |
| Max Price | US$5.11 |
| Entity | Company |
| Shares | 1,240 |
| Max Price | US$5.65 |
| Entity | Company |
| Shares | 2,015 |
| Max Price | US$5.65 |
| Entity | Individual |
| Shares | 2,122 |
| Max Price | US$5.65 |
| Entity | Individual |
| Shares | 506 |
| Max Price | US$5.65 |
| Entity | Individual |
| Shares | 228 |
| Max Price | US$5.59 |
| Entity | Company |
| Shares | 4,087 |
| Max Price | US$5.59 |
| Entity | Individual |
| Shares | 1,554 |
| Max Price | US$5.59 |
| Entity | Company |
| Shares | 7,655 |
| Max Price | US$6.14 |
| Entity | Company |
| Shares | 7,863 |
| Max Price | US$6.60 |
| Entity | Company |
| Shares | 15,114 |
| Max Price | US$6.55 |
Ownership Breakdown
Management Team
Ajay Gupta (61yo)
Chief Scientific Officer & Member of Scientific Advisory Board
- Tenure: 13.9yrs
- Compensation: US$954.42k
Stuart Paul (59yo)
President
- Tenure: 1.1yrs
- Compensation: US$7.48m
Jim McCarthy
Senior Vice President of Business & Corporate Development
- Tenure: 1.1yrs
Ray Pratt (68yo)
Chief Medical Officer
- Tenure: 7.5yrs
- Compensation: US$965.87k
Angus Smith (36yo)
Chief Financial Officer
- Tenure: 0.9yrs
- Compensation: US$1.45m
David Kull (52yo)
Executive Officer
- Tenure: 0.3yrs
Anne Boardman
Vice President of Sales and Strategic Accounts
- Tenure: 1yrs
Mike DeYoung
Vice President of Operations
- Tenure: 0.8yrs
Michael Costello
General Counsel
- Tenure: 0yrs
Paul McGarry (51yo)
VP, Corporate Controller & Principal Accounting Officer
- Tenure: 0.3yrs
Board Members
John Cooper (60yo)
Director
- Tenure: 2.1yrs
- Compensation: US$286.19k
Robin Smith (54yo)
Director
- Tenure: 3.3yrs
- Compensation: US$193.16k
Lisa Colleran (61yo)
Director
- Tenure: 1.6yrs
- Compensation: US$246.15k
Ben Wolin (43yo)
Chairman
- Tenure: 1.6yrs
- Compensation: US$306.85k
Ajay Gupta (61yo)
Chief Scientific Officer & Member of Scientific Advisory Board
- Tenure: 13.9yrs
- Compensation: US$954.42k
Rajiv Agarwal
Member of Scientific Advisory Board
- Tenure: 13.9yrs
Stuart Paul (59yo)
President
- Tenure: 1.1yrs
- Compensation: US$7.48m
Iain MacDougall
Member of Scientific Advisory Board
- Tenure: 9.2yrs
Alvin Crumbliss
Member of Scientific Advisory Board
- Tenure: 8.5yrs
Francesco Locatelli
Member of Scientific Advisory Board
- Tenure: 6.8yrs
Company Information
Rockwell Medical, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Rockwell Medical, Inc.
- Ticker: RMTI
- Exchange: NasdaqGM
- Founded: 1994
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$152.541m
- Shares outstanding: 63.82m
- Website: https://www.rockwellmed.com
Number of Employees
Location
- Rockwell Medical, Inc.
- 30142 Wixom Road
- Wixom
- Michigan
- 48393
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| RMTI | NasdaqGM (Nasdaq Global Market) | Yes | Common Shares | US | USD | Jan 1998 |
| RWM | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Jan 1998 |
Biography
Rockwell Medical, Inc. operates as a specialty pharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and he ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/17 23:44 |
| End of Day Share Price | 2019/10/17 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.